These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 28807457)

  • 1. Identification of pseudobulbar affect symptoms in the nursing home setting: Development and assessment of a screening tool.
    Allen C; Zarowitz B; O'Shea T; Peterson E; Yonan C; Waterman F
    Geriatr Nurs; 2018; 39(1):54-59. PubMed ID: 28807457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dextromethorphan/quinidine for the treatment of pseudobulbar affect.
    Patatanian E; Casselman J
    Consult Pharm; 2014 Apr; 29(4):264-9. PubMed ID: 24704895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Compounded Dextromethorphan-Quinidine Suspension for Pseudobulbar Affect in Hospice Patients.
    Wahler RG; Reiman AT; Schrader JV
    J Palliat Med; 2017 Mar; 20(3):294-297. PubMed ID: 27997281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dextromethorphan/quinidine sulfate for pseudobulbar affect.
    Rosen H
    Drugs Today (Barc); 2008 Sep; 44(9):661-8. PubMed ID: 19137121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.
    Hammond FM; Alexander DN; Cutler AJ; D'Amico S; Doody RS; Sauve W; Zorowitz RD; Davis CS; Shin P; Ledon F; Yonan C; Formella AE; Siffert J
    BMC Neurol; 2016 Jun; 16():89. PubMed ID: 27276999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.
    Pattee GL; Wymer JP; Lomen-Hoerth C; Appel SH; Formella AE; Pope LE
    Curr Med Res Opin; 2014 Nov; 30(11):2255-65. PubMed ID: 25062507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results.
    Doody RS; D'Amico S; Cutler AJ; Davis CS; Shin P; Ledon F; Yonan C; Siffert J
    CNS Spectr; 2016 Dec; 21(6):450-459. PubMed ID: 26471212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dextromethorphan-quinidine-responsive pseudobulbar affect (PBA): psychopharmacological model for wide-ranging disorders of emotional expression?
    Stahl SM
    CNS Spectr; 2016 Dec; 21(6):419-423. PubMed ID: 27855728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, behavioral, and treatment differences in nursing facility residents with dementia, with and without pseudobulbar affect symptomatology.
    Zarowitz BJ; O'Shea T
    Consult Pharm; 2013 Nov; 28(11):713-22. PubMed ID: 24217191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of pseudobulbar affect symptoms and clinical correlates in nursing home residents.
    Foley K; Konetzka RT; Bunin A; Yonan C
    Int J Geriatr Psychiatry; 2016 Jul; 31(7):694-701. PubMed ID: 26526856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic use of dextromethorphan: key learnings from treatment of pseudobulbar affect.
    Miller A; Panitch H
    J Neurol Sci; 2007 Aug; 259(1-2):67-73. PubMed ID: 17433820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of pseudobulbar affect including a novel and potential therapy.
    Schiffer R; Pope LE
    J Neuropsychiatry Clin Neurosci; 2005; 17(4):447-54. PubMed ID: 16387982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect.
    Fralick M; Sacks CA; Kesselheim AS
    JAMA Intern Med; 2019 Feb; 179(2):224-230. PubMed ID: 30615021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dextromethorphan/quinidine: in pseudobulbar affect.
    Garnock-Jones KP
    CNS Drugs; 2011 May; 25(5):435-45. PubMed ID: 21476614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recognizing and treating pseudobulbar affect.
    Sauvé WM
    CNS Spectr; 2016 Dec; 21(S1):34-44. PubMed ID: 28044945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudobulbar affect: an under-recognized and under-treated neurological disorder.
    Work SS; Colamonico JA; Bradley WG; Kaye RE
    Adv Ther; 2011 Jul; 28(7):586-601. PubMed ID: 21660634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments.
    Miller A; Pratt H; Schiffer RB
    Expert Rev Neurother; 2011 Jul; 11(7):1077-88. PubMed ID: 21539437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of dextromethorphan/quinidine on auditory event-related potentials in multiple sclerosis patients with pseudobulbar affect.
    Haiman G; Pratt H; Miller A
    J Clin Psychopharmacol; 2009 Oct; 29(5):444-52. PubMed ID: 19745644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study.
    Hammond FM; Sauve W; Ledon F; Davis C; Formella AE
    PM R; 2018 Oct; 10(10):993-1003. PubMed ID: 29477412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing Approaches to the Identification and Management of Pseudobulbar Affect.
    Crumpacker DW
    J Clin Psychiatry; 2016 Sep; 77(9):e1155. PubMed ID: 27780330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.